Epigenomics Poised to Enter Cancer Diagnostics Market with DNA Methylation Marker Technology

Author：

ISSN： 1176-3469

Source： Pharmaceutical & Diagnostic Innovation, Vol.2, Iss.5, 2004-10, pp. : 51-55

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics

Current Pharmaceutical Design, Vol. 20, Iss. 11, 2014-04 ,pp. : 1812-1818

Bentham Science Publishers

Access to resources Recommend Favorite

Cancer Diagnostics: Decision Criteria for Marker Utilization in the Clinic

By Taube Sheila E. Jacobson James W. Lively Tracy G.

American Journal of PharmacoGenomics, Vol. 5, Iss. 6, 2005-01 ,pp. : 357-364

Adis International

Access to resources Recommend Favorite

Epigenomics and breast cancer

By Lo Pang-Kuo Sukumar Saraswati

Pharmacogenomics, Vol. 9, Iss. 12, 2008-12 ,pp. : 1879-1902

Future Medicine

Access to resources Recommend Favorite

DNA Methylation Patterns in Cancer: Novel Prognostic Indicators?

By Frühwald M.C.

American Journal of PharmacoGenomics, Vol. 3, Iss. 4, 2003-01 ,pp. : 245-260

Adis International

Access to resources Recommend Favorite

Identifying DNA Methylation Biomarkers of Cancer Drug Response

By Maier Sabine

American Journal of PharmacoGenomics, Vol. 5, Iss. 4, 2005-01 ,pp. : 223-232

Adis International

Access to resources Recommend Favorite